Cytokinetics' MYQORZO Launch Exceeds Expectations with Strong Q1 Demand

Event summary

  • MYQORZO (aficamten) generated $4.8M in net product revenue in Q1 2026, with over 680 patients prescribed the drug.
  • ACACIA-HCM trial met dual primary endpoints, showing significant improvements in KCCQ and maximal exercise performance.
  • European Commission approved MYQORZO for symptomatic obstructive HCM, with launch expected in Germany in Q2 2026.
  • Supplemental NDA for MAPLE-HCM accepted by FDA with a PDUFA date of November 14, 2026.
  • Cash position declined by $144M to $1.1B as of March 31, 2026.

The big picture

Cytokinetics' strong Q1 performance with MYQORZO underscores the growing market for cardiac myosin inhibitors. The positive ACACIA-HCM results expand the potential patient population, while regulatory approvals in Europe and the pending FDA decision for MAPLE-HCM position the company for further growth. The biopharmaceutical sector is increasingly focused on targeted therapies for rare cardiovascular diseases, and Cytokinetics' pipeline reflects this trend.

What we're watching

Commercial Momentum
Whether Cytokinetics can sustain the strong initial demand for MYQORZO and expand its prescriber base.
Regulatory Milestones
The pace at which Cytokinetics secures additional regulatory approvals for aficamten, particularly in Japan and Switzerland.
Financial Sustainability
How Cytokinetics manages its cash burn rate amid increasing commercialization costs and potential future funding needs.